Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 12/20 | 0.82 |
| ▸ | PTAFR | P25105 | 3/20 | 0.77 |
| ▸ | FNTA | P49354 | 4/20 | 0.76 |
| ▸ | FNTB | P49356 | 4/20 | 0.76 |
| ▸ | SLC6A15 | Q9H2J7 | 4/20 | 0.76 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.72 |
| ▸ | HTR1A | P08908 | 2/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.72 |
| ▸ | DRD2 | P14416 | 2/20 | 0.72 |
| ▸ | HTR2A | P28223 | 2/20 | 0.72 |
| ▸ | HTR2C | P28335 | 2/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.72 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.72 |
| ▸ | HTR2B | P41595 | 2/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.72 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29626502 | 1.00 | HRH1 (0.82) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL31384618 | 1.00 | HRH1 (0.82) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL20777155 | 0.89 | PTAFR (0.75) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL8958672 | 0.89 | PTAFR (0.75) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL10123931 | 0.88 | HRH1 (1.00) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL10108533 | 0.88 | HRH1 (0.72) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL11925299 | 0.88 | HRH1 (1.00) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL26488239 | 0.88 | SLC6A15 (0.79) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL8876967 | 0.87 | PTAFR (1.00) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL31305643 | 0.87 | PTAFR (1.00) | HRH1PTAFRFNTAFNTBSLC6A15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002349-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD BIOSCIENCE INC. (KR) | 2023-01-05 | — | — | US | claimed |
| EP-4053116-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD Bioscience Inc. (KR) | 2022-09-07 | — | — | EP | claimed |
| WO-2021086133-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | (주)제이디바이오사이언스 | 2021-05-06 | — | — | WO | claimed |
| US-20080194823-A1 | PREPARATION OF LORATADINE FORM I | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-08-14 | — | — | US | claimed |
| EP-0152897-B1 | 8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta-[1,2-b]pyridine and its salts, processes for the production thereof and pharmaceutical compositions containing these compounds | SCHERING CORPORATION (US) | 1989-10-11 | — | — | EP | claimed |
| EP-0152897-A1 | 8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta-[1,2-b]pyridine and its salts, processes for the production thereof and pharmaceutical compositions containing these compounds | SCHERING CORPORATION (US) | 1985-08-28 | — | — | EP | claimed |
| EP-4177248-A1 | A CLASS OF TRICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Hefei Institute of Pharmaceutical Industry Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023071601-A1 | DESLORATADINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 天津市昕晨投资发展有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2023284782-A1 | METHOD FOR SCREENING COMPOUND FOR TREATING OR PREVENTING MHTT-RELATED NEURODEGENERATIVE DISEASES, TARGET PROTEIN, AND COMPOUND | 复旦大学 | 2023-01-19 | — | — | WO | disclosed |
| CN-115616122-A | Method for separating and measuring related substances of loratadine starting material by liquid chromatography | 北京万全德众医药生物技术有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20230002349-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD BIOSCIENCE INC. (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20230002349-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD BIOSCIENCE INC. (KR) | 2023-01-05 | — | — | US | disclosed |
| EP-4053116-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD Bioscience Inc. (KR) | 2022-09-07 | — | — | EP | disclosed |
| US-4863931-A | ANTIALLERGENS | SCHERING CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| US-4826853-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0270818-A1 | Benzo(5,6)cycloheptapyridines, compositions and method of use | SCHERING CORPORATION (US) | 1988-06-15 | — | — | EP | disclosed |
| WO-1988003138-A1 | BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1988-05-05 | — | — | WO | disclosed |
| US-4659716-A | Antihistaminic 8-(halo)-substituted 6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridines | SCHERING CORPORATION (US) | 1987-04-21 | — | — | US | disclosed |
| EP-0208855-A1 | Process for preparing piperidylidene dihydrodibenzo(a,d)cycloheptenes and aza derivatives thereof, compounds obtained by such process and the use of such compounds for preparing useful pharmaceutical compositions | SCHERING CORPORATION (US) | 1987-01-21 | — | — | EP | disclosed |
| EP-0152897-A1 | 8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta-[1,2-b]pyridine and its salts, processes for the production thereof and pharmaceutical compositions containing these compounds | SCHERING CORPORATION (US) | 1985-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194823-A1 | PREPARATION OF LORATADINE FORM I | HTR1B, HTR1D, CYP1A1 | HRH1 10/4885PTAFR 3219/4885FNTA 4082/4885 |
| US-20230002349-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TPH1, SLC6A4, TPH2 | HRH1 1035/4885PTAFR 1723/4885FNTA 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.